Product image of Melfalano Eugia (Melphalan) supplied by GNH India

Melfalano Eugia

Active Ingredient:
Melphalan
Origin:
EU

Melfalano Eugia (Melphalan)

Melphalan, the active ingredient in Melfalano Eugia, is an alkylating agent presented as an injectable solution for intra‑arterial and intravenous use. It is employed in the treatment of certain hematologic and solid tumours, particularly in adult patients with multiple myeloma, ovarian cancer or malignant melanoma.

GNH India supplies Melfalano Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melphalan is used as an antineoplastic agent targeting rapidly dividing cancer cells in several malignancies.

  • Multiple myeloma: reduces tumor burden and prolongs survival in patients with relapsed or refractory disease.
  • Ovarian cancer: contributes to tumor shrinkage and improves response rates when combined with other chemotherapeutics.
  • Malignant melanoma: provides cytoreductive activity in advanced‑stage disease, often as part of combination regimens.

How It Works

  • Melphalan exerts its cytotoxic effect by alkylating nucleophilic sites on DNA, forming intra‑ and interstrand cross‑links that impede DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly proliferating malignant cells while sparing most normal tissues. The alkyl groups preferentially bind to the N7 position of guanine, leading to mispairing and strand breaks that the tumor cell cannot efficiently repair.

Side Effects

Melphalan may cause a range of adverse reactions, varying from mild to severe, that are monitored during therapy.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset occurring during or after infusion.
  • Bone marrow suppression: decreased white blood cells, red cells, and platelets.
  • Fatigue: generalized tiredness affecting daily activities.
  • Alopecia: temporary hair loss on scalp and body.

Serious or Rare Side Effects

  • Secondary malignancies: development of new cancers such as leukemia.
  • Severe infection: opportunistic infections due to profound neutropenia.
  • Pulmonary fibrosis: progressive scarring of lung tissue leading to respiratory compromise.

Precautions & Warnings

Prior to initiating melphalan therapy, clinicians should evaluate patient history and implement safety measures to minimize risks.

  • Baseline blood counts: obtain complete blood count to assess marrow function before each cycle.
  • Renal function: monitor serum creatinine and adjust dosing in patients with impaired clearance.
  • Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks.
  • Concomitant myelosuppressive agents: use caution when combined with other chemotherapy that depresses bone marrow.
  • Store at ambient temperature: keep vials below 25 °C, protect from light and moisture, and retain in original packaging.

Avoid Interactions

Melphalan can interact with other medicines, altering its efficacy or increasing toxicity; awareness of key interactions guides safe prescribing.

Major Interactions (Avoid)

  • Live vaccines: concurrent administration may cause uncontrolled infection due to immunosuppression.
  • Strong CYP450 inducers: agents such as rifampin can reduce melphalan plasma levels, diminishing therapeutic effect.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles: may increase melphalan exposure and heighten myelosuppression risk.
  • Allopurinol: can potentiate hematologic toxicity; monitor blood counts closely.
  • NSAIDs: may exacerbate renal impairment when used with melphalan; assess renal function regularly.

Frequently Asked Questions

Melfalano Eugia contains melphalan, an alkylating antineoplastic agent indicated for the treatment of multiple myeloma, ovarian cancer and malignant melanoma. It is administered by healthcare professionals as part of a chemotherapy regimen aimed at controlling tumor growth in these malignancies.

Melphalan works by adding alkyl groups to DNA bases, primarily at the N7 position of guanine. This creates cross‑links that block DNA replication and transcription, leading to cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells.

The dose of Melfalano Eugia is individualized by the prescribing oncologist based on factors such as the specific cancer type, disease stage, patient weight, renal function, and prior treatment history. No fixed dosing schedule is provided publicly; the prescriber sets the regimen.

Safety data for melphalan in pregnancy and lactation are limited, and the drug is generally contraindicated because of potential fetal toxicity and excretion in breast milk. Use is only considered if the potential benefit justifies the risk to the fetus or infant.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to alkylating agents but differs in its pharmacokinetic profile and spectrum of activity. Compared with agents such as cyclophosphamide, melphalan is often preferred for certain hematologic malignancies and for high‑dose regimens prior to stem‑cell transplantation.

Melfalano Eugia should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from light, moisture and extreme temperature fluctuations to maintain stability until it is prepared for administration.

The product is supplied as a sterile injectable solution and is given by a qualified healthcare professional via intra‑arterial or intravenous infusion. Administration settings, infusion rates and pre‑medication protocols are determined by the treating physician based on clinical guidelines.

The most serious risks include severe bone‑marrow suppression leading to life‑threatening infections or bleeding, the development of secondary malignancies such as therapy‑related leukemia, and organ toxicity like pulmonary fibrosis. Patients are monitored closely for these complications throughout treatment.

Melfalano Eugia is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in pregnant or breastfeeding women unless absolutely necessary, and in individuals with severe uncontrolled infections or organ dysfunction that would preclude safe administration.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Melphalan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT